science
Biotech Firms Ask Trump Administration to Shield Rare-Disease Drugs from Medicare Price Pilots
Biotech firms are pressing the White House to exclude treatments for rare diseases from two Medicare pilot programs that lower brand drug prices. The Rare Disease Company Coalition met last week with the Office of Management and Budget to discuss the request.
Jul 21, 4:30 AM·1m read2 sources
theconservativetreehouse.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that lower brand drug prices in Medicare. The Rare Disease Company Coalition met last week with the White House Office of Management and Budget to discuss two pilot programs. The programs form part of President Trump’s plan to align U.S.
Drug prices with those charged in other wealthy countries under a most-favored nation approach. Exempting orphan drugs would shrink pilots that already exclude at least some major drugmakers, a July 21 STAT report stated.
